Quick Answer
Editas Medicine, Inc. reported Diluted EPS of $1.80 per share (loss) for fiscal year 2025.
Editas Medicine, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.80 | +37.5% |
| 2024 | -$2.88 | -42.6% |
| 2023 | -$2.02 | +37.1% |
| 2022 | -$3.21 | -12.6% |
| 2021 | -$2.85 | -43.9% |
| 2020 | -$1.98 | +26.1% |
| 2019 | -$2.68 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.28 | +62.7% | +55.6% |
| June 30, 2025 | -$0.63 | +23.2% | +31.5% |
| March 31, 2025 | -$0.92 | -21.1% | -22.7% |
| September 30, 2024 | -$0.75 | -36.4% | +8.5% |
| June 30, 2024 | -$0.82 | -46.4% | -7.9% |
| March 31, 2024 | -$0.76 | -7.0% | -38.2% |
| September 30, 2023 | -$0.55 | +32.1% | +1.8% |
| June 30, 2023 | -$0.56 | +28.2% | +21.1% |
- Editas Medicine, Inc. showed an increase of +37.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Editas Medicine, Inc.’s diluted eps has grown by 32.8% (from $2.68 per share (loss) to $1.80 per share (loss)).
- The most recent figure is from Editas Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: